Research programme: Parkinson's disease therapy - OptiNose

Drug Profile

Research programme: Parkinson's disease therapy - OptiNose

Alternative Names: OPT 1037; Parkinson's disease therapy research programme - OptiNose

Latest Information Update: 08 Mar 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OptiNose AS
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Parkinson's disease

Most Recent Events

  • 08 Mar 2006 This programme is still in active development - (BPN-2006)
  • 06 Feb 2005 The Parkinson's disease therapy programme of OptiNose is available for partnering worldwide (http://www.optinose.no)
  • 06 Feb 2005 Preclinical trials in Parkinson's disease in Norway (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top